Interleukin-23 in Psoriasis: Integrating New Therapies in the Current Treatment Landscape

Prof Reich welcomed delegates to the satellite symposium and explained that the aims of the meeting were to introduce the clinical role of targeted interleukin (IL)-23 therapies in psoriasis, show why IL-23 therapy is effective against psoriasis, show how it works in patients by illustrating emerging clinical trial data, and, finally, describe how the IL-23 inhibitors can be used to address unmet clinical needs in patients with psoriasis. Dr Blauvelt started the meeting by providing an update on the current understanding of the immunology of cytokine pathways in psoriasis. Prof Reich then gave an overview of the clinical value of IL-23 inhibitors as novel targeted treatments for psoriasis, summarising data from pivotal clinical trials that have been carried out to support the introduction of these treatments into the clinical armamentarium. Finally, Prof Girolomoni reviewed the indications for biologic therapies and discussed how IL-23 inhibitors can be integrated into the current therapeutic environment. The satellite symposium concluded with a lively question and answer session